Company intelligence / Profile preview

HQ Specialty Pharma

Paramus, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

HQ Specialty Pharma is the innovation and product development unit of PharmaSphere, specializing in ready-to-use (RTU) hospital injectables. They have successfully received FDA approvals for multiple first-in-class RTU formulations, including Levetiracetam in Sodium Chloride and Calcium Gluconate in flexible containers. Their most recent significant approvals include Exblifep (cefepime + enmetazobactam) in 2024 and Meropenem for injection in 2023. They are currently involved in patent litigation with competitors like Fresenius Kabi and Cipla regarding their RTU bag technology.

Therapeutic areas: EndocrinologyNeurologyCardiovascularInfectious Diseases
Modalities: Small moleculeInjectableReady-to-use bag
Industry: Biotech

Partnerships

WG Critical CareWelGrace Research GroupInfoRLifeCaplin Steriles

Beyond the preview

Go deeper on HQ Specialty Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HQ Specialty Pharma.

Explore the full profile